Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Language: German
    In: Informationstechnik,
    Description: Das Mobilfunksystem GSM (Global System for Mobile Communication) wurde von Anfang an sehr erfolgreich in ganz Europa und auch in vielen außereuropäischen Ländern eingesetzt. Es ist mittlerweile zu einem wirklich globalen System herangewachsen - der GSM-Anteil am Weltmarkt der digitalen Mobilfunksysteme betrug Ende 1998 über 60% und die Teilnehmerzahlen hatten sich innerhalb eines Jahres verdoppelt. Das Buch stellt auf der Grundlage der europäischen GSM-Standards die technischen Grundlagen und die Systemarchitektur von GSM vor. Dabei liegen die Schwerpunkte auf der Darstellung der Protokolle, der Mobilvermittlungstechnik und der Dienstrealisierung. Die wichtigsten Prinzipien der GSM-Übertragungstechnik werden ebenfalls behandelt. Die erweiterte und aktualisierte Neuauflage enthält zusätzlich vor allem eine ausführliche Beschreibung des General Packet Radio Service (GPRS) und einen aktuellen Überblick zum Stand der Entwicklung der dritten Mobilfunkgeneration UMTS/IMT-2000. Angesprochen sind Studierende der Elektrotechnik, Informationstechnik und Informatik von Universitäten und Fachhochschulen, Anwender und Praktiker aus der Industrie, von Netzbetreibern und aus der Forschung, die sich einen fundierten Einblick in die Funktionsweise des komplexen Systems GSM verschaffen wollen und vor allem am Zusammenspiel der verschiedenen Funktionen interessiert sind. Für dieses Werk stehen unter einem Link auf der Homepage des Buches (http://www.lkn.ei.tum.de/gsm_buch/errata_Aufl2.html) Errata-Webseiten zur Verfügung.
    Keywords: Engineering ; Engineering ; Engineering, General ; Engineering
    ISBN: 9783322918581
    ISBN: 3322918580
    ISBN: 9783322940636
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Recent Results in Cancer Research, Cancer Prevention II, pp.113-119
    Description: The NSABP Study of Tamoxifen and Raloxifene (STAR), launched in 1999, compared tamoxifen with raloxifene in a population of healthy postmenopausal women at increased risk for breast cancer to determine the relative effects on the risk of invasive breast cancer. To be eligible for participation, a woman had to be healthy with at least a 5-year predicted breast cancer risk of 1.66% based on the Gail model or a history of lobular carcinoma in situ (LCIS) treated by local excision alone. All participants were at least 35 years of age and postmenopausal. Between July 1999 and November 2004, 19,747 participants were randomized to receive either tamoxifen (20 mg, plus placebo) or raloxifene (60 mg, plus placebo) daily for a 5-year period. The mean age of the participants was 58.5 years; 93% were white and 51.6% had a hysterectomy prior to entering the study. Of the women, 71% had one or more first degree female relatives (mother, sister, daughter) with a history of breast cancer and 9.2% of the women had a personal history of LCIS. A history of atypical hyperplasia of the breast was noted in 22.7% of the participants. The mean predicted 5-year risk of developing breast cancer among the study population was 4.03% (SD, 2.17%) with a lifetime predicted risk of 16%. The mean time of follow-up is 3.9 years (SD, 1.6 years). There was no difference between the effect of tamoxifen and the effect of raloxifene on the incidence of invasive breast cancer; there were 163 cases of invasive breast cancer in the tamoxifen-treated group and 168 cases in those women assigned to raloxifene (incidence 4.30 per 1,000 vs 4.41 per 1,000; RR 1.02; 95% CI, 082–1.28). There were fewer cases of noninvasive breast cancer (LCIS and ductal carcinoma in situ [DCIS]) in the tamoxifen group (57 cases) than in the raloxifene group (80 cases), although the difference is not yet statistically significant (incidence 1.51 vs 2.11 per 1,000; RR, 1.40; 95% CI, 0.98–2.00). There were 36 cases of uterine cancer with tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35–1.08).
    Keywords: Medicine & Public Health ; Oncology ; Cancer Research ; Medicine
    ISBN: 9783540692966
    ISBN: 3540692967
    Source: SpringerLink Books
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages